Janssen tie-up will give Idenix data on IDX719 ahead of wholly-owned HCV combo studies
This article was originally published in Scrip
Executive Summary
Through a non-exclusive collaboration with Janssen Pharmaceuticals to run Phase II clinical trials for all-oral combinations of hepatitis C virus (HCV) drugs, Idenix Pharmaceuticals will have multiple chances to test the safety and efficacy of IDX719 prior to running mid-stage trials with a wholly-owned combination therapy that includes the pan-genotypic NS5A inhibitor and a new internally developed nucleotide inhibitor.